NC-KBI-BIOPHARMA
15.4.2024 14:01:35 CEST | Business Wire | Press release
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Jean-Baptiste (JB) Agnus as Chief Business Officer, solidifying KBI’s Executive Team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415842099/en/
JB Agnus, Chief Business Officer, KBI Biopharma, Inc. (Photo: Business Wire)
JB brings more than two decades of experience across various sectors of the biopharmaceutical industry with expertise in commercial development in biologics, small molecule APIs, antibody-drug conjugates (ADCs), and the latest advancements in cell and gene therapies. With a proven track record of implementing winning sales strategies and cultivating high-performing teams, JB will lead KBI’s global business development initiatives, driving the company towards continued growth and sustained success. This pivotal role is focused on building and maintaining long-lasting partnerships with KBI’s current and future customers around the globe. JB’s commitment to fostering relationships with external partners and internal team members alike is a value that aligns well with KBI’s collaborative culture.
“Our dedication to growth and commitment to our partners, their patients, and our people guide every decision at KBI Biopharma,” remarked J.D. Mowery, President & CEO of KBI Biopharma. “JB’s appointment underscores this dedication, perfectly aligning with our team’s mission to deliver innovative, top-tier solutions tailored to our customers' evolving needs. His servant leadership philosophy will further fortify our team, propelling KBI to new heights.”
“KBI Biopharma is an innovator in the testing, development, manufacturing, and commercialization of life-changing therapies,” said JB Agnus, Chief Business Officer of KBI Biopharma. “Strong partnerships are at the core of KBI’s success. I am excited to join the passionate team at KBI, who are committed to ensuring transformative treatments reach those in need by nurturing meaningful customer relationships.”
Before joining KBI, JB held leadership roles in business development at AGC Biologics, Ajinomoto Bio-Pharma Services, Novasep, and Isochem. He holds a Master of Science in Chemical Engineering from Centrale Marseille.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, and microbial programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with six locations in Europe and the USA. More information is available at www.kbibiopharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415842099/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CreditNature and Stabiliti Partner to Embed Nature Finance into Everyday Economic Activity19.5.2026 14:48:00 CEST | Press release
CreditNature, a leading international Nature Fintech company, is proud to announce a strategic partnership with Stabiliti, which enables businesses to seamlessly integrate verified nature restoration into core economic activity and financial flows, unlocking scalable investment for ecosystem recovery. CreditNature, a pioneering Nature Fintech company, today announces a strategic partnership with Stabiliti, a nature-focused technology company building the infrastructure to embed environmental contributions into everyday economic activity. Together, the partnership will enable businesses to embed measurable nature impact into everyday operations, bridging the gap between commercial activity and ecosystem restoration at unprecedented scale. The collaboration addresses a critical challenge in nature finance: how to mobilise investment at the scale required to meet global biodiversity targets. By integrating CreditNature's scientifically accredited NARIA framework with Stabiliti's embedded
Gustave Roussy and One Biosciences Partner to Bring Single Cell to Clinical Practice for Precision Oncology19.5.2026 13:02:00 CEST | Press release
Gustave Roussy partners with One Biosciences, a techbio company that harnesses single cell technology and AI to develop advanced precision diagnostics. The collaboration aims to further demonstrate the feasibility and impact of integrating single nuclei transcriptomic analysis into the patient care pathway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519540709/en/ Gustave Roussy, Europe’s leading cancer center, is teaming up with One Biosciences to harness the cutting-edge potential of OneMapTM, the single-cell and AI-powered solution helping to enhance precision oncology solutions. By analyzing anonymized frozen samples across four cancer indications, One Biosciences will deploy OneMapTM to generate ultra-high-resolution single-cell data, unlocking the hidden functional diversity of each tumor with unparalleled precision. Prof. Sophie Postel-Vinay, oncologist at Gustave Roussy, team leader in Inserm unit U981 at Gusta
InterSystems IntelliCare Becomes the First AI-Native EHR to Achieve EU Medical Device Regulation Certification19.5.2026 13:00:00 CEST | Press release
Regulatory milestone reaffirms InterSystems as a leading provider of enterprise-grade AI applications InterSystems, a creative data technology provider powering more than one billion health records globally, today announced that its electronic health record (EHR) solutions have been certified as Class IIa Medical Devices under Regulation (MDR) certification under Regulation (EU) 2017/745. This approval marks the first fully unified AI-native EHR to achieve MDR Class IIa certification in the European Union. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519124986/en/ This certification demonstrates that InterSystems AI-native EHR meets stringent EU safety and quality standards. This key milestone has significant implications for how healthcare organizations can responsibly scale AI while building confidence among healthcare providers and regulators. InterSystems has secured MDR certification for InterSystems IntelliCare™,
Venionaire Capital Mandated to Structure KISAB’s Next Growth Round19.5.2026 12:41:00 CEST | Press release
Growth round to target growth private equity and strategic investors as KISAB advances its 8-inch BPD-free SiC wafer platform Venionaire Capital has been mandated by Kiselkarbid i Stockholm AB (“KISAB”) to structure and support the company’s next growth round. The mandate includes investor relations, investor communications and strategic financing preparation, targeting growth private equity and strategic investors. KISAB is a Sweden-based silicon carbide semiconductor materials company focused on advanced SiC substrates for power electronics. The company publicly highlights its 8-inch BPD-free n-type silicon carbide wafers, with the 8-inch platform representing an important technological step for next-generation high-performance power electronics. KISAB has previously attracted approximately EUR 24 million across several financing rounds. Publicly named investors include Fairpoint Capital, Industrifonden and Ingka GreenTech. Venionaire Capital will now support the company in sharpenin
motif Launches Clarity, a First-of-Its-Kind AI Financial Intelligence System19.5.2026 12:39:00 CEST | Press release
Clarity applies contextual understanding to market intelligence, enabling auditable, high-quality AI wealth advisory for financial institutions motif, the AI wealth advisory company backed by Liminal (a venture creation group founded by Temasek), today launched Clarity, an AI financial intelligence system that tracks how markets, assets and financial relationships connect, and how and why they change over time, building enriched connections that deliver the kind of structured, sourced insight that financial institutions have never had, even with dedicated analyst teams. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511241653/en/ motif Launches Clarity, a First-of-Its-Kind AI Financial Intelligence System Financial institutions integrate Clarity into their products so customers can make better-informed investment decisions, while analysts and product teams use it to track market shifts and plan accordingly. Informed inves
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom